hvsa
Home
Courses
Course Objectives
Programs
CME Credits
Cases and Abstract Submissions
venue and accomodations
HVSA
Directors and Faculty
Videos
Register

 

New York City Conference

Back to 2014 Annual Meeting Abstracts


Does Left Ventricular Hypertrophy Affect Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement?
Nimesh Desai, Tyler Wallen, Saif Anwaruddin, Prashanth Vallabhajosyula, Rohan Menon, Howard Herrmann, Wilson Szeto, Joseph Bavaria.
University of Pennsylvania, Philadelphia, PA, USA.

OBJECTIVE: Severe left ventricular hypertrophy (LVH) has a well documented severe negative impact on early mortality in patients undergoing surgical aortic valve replacement. This effect is particularly pronounced in patients with elevated relative wall thickness, an indicator of extreme hypertrophy with small ventricular cavity(suicide ventricle). It is not clear whether similar mortality risk is present in transcatheter aortic valve replacement(TAVR), which avoids issues regarding myocardial protection and hyperdynamic post-bypass physiology. The purpose of this study is to analyze the impact of LVH on patients undergoing TAVR.
METHODS: From 2008-2011, a retrospective review of patients undergoing tAVR was performed, comparing patients without severe LVH (n=59) to those with severe LVH (group 2, n=89). LVH was defined as a relative wall thickness (2xPosterior wall Thickness/LVEDD) of greater than 0.5. Data was abstracted from a prospectively kept database with robust echocardiographic and clinical follow-up.
RESULTS: From 2008-2011, a retrospective review of patients undergoing tAVR was performed, comparing patients without severe LVH (n=59) to those with severe LVH (group 2, n=89). LVH was defined as a relative wall thickness (2xPosterior wall Thickness/LVEDD) of greater than 0.5. Data was abstracted from a prospectively kept database with robust echocardiograhpic and clinical follow-up.
CONCLUSIONS: Unlike surgical AVR patients, the presence of severe left ventricular hypertrophy in patients undergoing TAVR was not correlated with adverse outcomes at 1 year.


Back to 2014 Annual Meeting Abstracts

     

Home | Courses | Objectives | Program | CME Credit | Cases & Abstracts | Venu & Accomodations | HVSA | Committee & Faculty | Register | Privacy Policy